title: In vivo formation of metabolites of prostaglandins I2 and I3 in the marmoset monkey (Callithrix jacchus) following dietary supplementation with tuna fish oil.
abstract: Recent studies have shown that ingestion of eicosapentaenoic acid (EPA) in man results in the formation of 'trienoic' prostanoids which amy partly explain the potent antithrombotic/antiatherogenic properties of long-chain polyunsaturated n-3 fatty acids (PUFAs). However, endogenous formation of cyclooxygenase metabolites of EPA has not been demonstrated in an animal model, and in vitro studies indicate a clear species difference in the conversion of EPA to PGI3. Thus, in the present study, the in vivo formation of PGI3 following long-term dietary tuna fish oil supplementation was investigated in a small non-human primate - the marmoset monkey (Callithrix jacchus). The excretion of major urinary metabolites 2,3-dinor-6-keto-PGF1 alpha (PGI2-M) and delta 17-2,3-dinor-6-keto-PGF1 alpha (PGI3-M) was estimated as an index of total body synthesis of PGI2 and PGI3, respectively. Following extraction, dinor prostanoid metabolites were separated by capillary gas chromatography and identified by negative ion chemical ionization mass spectrometry. Supplementation of the standard (reference) diet with either sheep fat or sunflower seed oil did not alter the body production of PGI2-M. However, following the tuna fish oil-enriched diet, there occurred not only an increase in urinary PGI2-M (reference 70.7 +/- 9.0; tuna fish oil 115.5 +/- 12.1 ng/g creatinine, P less than 0.05), but also a considerable formation of PGI3-M (62.9 +/- 5.3 ng/g creatinine), which was not seen in any other dietary group; in addition, the urinary level of immmunoreactive 2,3-dinor-thromboxane B2/3 was reduced after ingestion of tuna fish oil. These urinary changes were accompanied by a rise in plasma phospholipid-bound EPA and docosahexaenoic acid (DHA). In addition, tuna fish oil supplementation resulted in a significant reduction in plasma cholesterol (53%) and triacylglycerols (44%). The present study provides for the first time experimental evidence for the in vivo formation of PGI3 in an animal model and also confirms the earlier observations in man following dietary fish oil supplementation.
authors.affiliation: CSIRO, Division of Human Nutrition, Glenthorne Laboratory, O'Halloran Hill, Australia.
authors.forename: M Y
authors.initials: MY
authors.lastname: Abeywardena
authors.forename: S
authors.initials: S
authors.lastname: Fischer
authors.forename: H
authors.initials: H
authors.lastname: Schweer
authors.forename: J S
authors.initials: JS
authors.lastname: Charnock
mesh_terms: D000818:Animals; D002144:Callithrix; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D011464:Epoprostenol / Q000652:urine* / Q000031:analogs & derivatives; D005227:Fatty Acids / Q000097:blood; D005395:Fish Oils / Q000008:administration & dosage*; D008297:Male; D014413:Tuna
chemical_list: D004042:Dietary Fats, Unsaturated; D005227:Fatty Acids; D005395:Fish Oils; C034240:prostaglandin I3; D011464:Epoprostenol